Clinical Research Directory

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate diagnosed within 360 days of enrollment. * Prostate Specific Antigen (PSA) documented within 90 days prior to registration. * Clinical staging completed within 90 days of registration. * No Nodal or Distant Metastases documented on CT or MRI of the pelvis and bone scan. * Unfavorable Risk Prostate Carcinoma as Described is documented. * No prior pelvic radiotherapy. * No prior Trans-urethral resection of the prostate (TURP). * Prostate volume \< 100 cc * American Urologic Association (AUA) score \< 20 * No recent (within 5 years) or concurrent cancers other than non-melanoma skin cancers. * Patient must have no medical or psychiatric illnesses that would interfere with treatment or follow-up. * No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery is allowed. * Candidate for rectal spacer placement Exclusion Criteria: * Other cancer diagnosis other than non-melanoma skin cancer with 5 years * Prostate size greater than 100cc * AUA greater than 20 * Implanted hardware impacting imaging * Metastatic prostate cancer * Contraindication to hormone therapy